SpringWorks Therapeutics: Q2 Earnings Snapshot sfgate.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sfgate.com Daily Mail and Mail on Sunday newspapers.
Published: May 13, 2021 By Alex Keown
Akouos, Inc. – Kathy Reape was named chief development officer of Boston-based Akouos. Reape most recently served as chief medical officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance, and medical affairs activities. Reape was a key member of the team responsible for the development and commercialization of Luxturna, the first FDA-approved in vivo gene therapy approved for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. Prior to Spark, Reape was senior vice president of clinical development focusing on global brands research and development at Allergan and Actavis.
CARMAT – France-based CARMAT’s board of directors is reorganizing its governance and appointed three new directors. The company tapped Florent Battistella, David Coti and John B. Hernandez as directors. Battistella founded Nisima, a holding company, which holds stakes in various firms, notably
Source: Shutterstock
While 97% of its sales are in the U.S., HZNP is one of those pharmaceuticals that moved its operations to Ireland for favorable tax status. With a $20 billion market cap, it’s one of the biggest pharma stocks on our list.
What’s more, it has a handful of drugs already in the market, earning money. HZNP focuses on rheumatic diseases as well as rare and orphan diseases. The rheumatic diseases like gout, mean long-term therapies as do the rare diseases. And the rare diseases usually only have one or two drugs to treat them, although their patient pool is small.
SpringWorks Therapeutics: Q1 Earnings Snapshot
May 6, 2021
FacebookTwitterEmail
STAMFORD, Conn. (AP) SpringWorks Therapeutics Inc. (SWTX) on Thursday reported a loss of $29.8 million in its first quarter.
The Stamford, Connecticut-based company said it had a loss of 62 cents per share.
The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 51 cents per share.
SpringWorks Therapeutics shares have decreased roughly 6% since the beginning of the year. The stock has more than doubled in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SWTX at https://www.zacks.com/ap/SWTX
Valdosta therapy clinic offers fast, easy service
Valdosta therapy clinic offers fast and easy service to the community By Jennifer Morejon | February 25, 2021 at 7:25 PM EST - Updated March 1 at 1:27 PM
VALDOSTA, Ga. (WALB) - With the pandemic causing stress, job loss, feelings of isolation, and hopelessness for many people, many therapy clinics are looking for new ways to give fast service to those who need it.
Valdosta State University’s
FamilyWorks Clinic wants you to know they’re available to help. Their new telehealth initiative allows people to text to start a session, wherever they are.
To begin, text “CONVO” to (229) 234-1435.